CJC 1295 + IPAMORELIN (5mg + 5mg)

CJC-1295 + Ipamorelin — Growth Hormone Research Peptide Blend

CJC-1295 + Ipamorelin combines two research peptides studied for their effects on growth-hormone signaling. CJC-1295 is a growth hormone–releasing hormone (GHRH) analog, while Ipamorelin is a growth hormone secretagogue that acts primarily through the ghrelin receptor. Together, they are researched for their potential complementary influence on growth hormone (GH) and downstream IGF-1 signaling.

Potential Areas of Research Interest:

• Growth Hormone Signaling — Studied for their ability to influence the body's GH-release pathways through two distinct mechanisms.

• GH & IGF-1 Research — Of interest in studies examining growth hormone secretion and downstream IGF-1 activity.

• Body Composition — GH-related research explores mechanisms involved in lean tissue maintenance, fat metabolism, and overall body composition.

• Recovery & Tissue Repair — Growth hormone and IGF-1 signaling are involved in biological processes associated with tissue growth, maintenance, and recovery.

• Muscle & Performance Research — Investigated in relation to GH-mediated pathways involved in protein metabolism and skeletal-muscle physiology.

• Sleep & Recovery — Natural growth hormone secretion is strongly associated with sleep, making GH-secretagogue pathways an area of interest in sleep and recovery research.

• Metabolic Research — Studied in connection with energy utilization, lipid metabolism, and other GH-related metabolic processes.

CJC-1295 and Ipamorelin remain investigational compounds and are not FDA-approved as a combination treatment. Proposed benefits should not be interpreted as established clinical outcomes, and safety and effectiveness depend on the specific compound and context being studied.

FOR RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION.